**Figure 1 A-D**

Figure 1A





Figure 1B





Figure 1C





Figure 1D




**Figure 1 E-H**

Figure 1E





Figure 1F





Figure 1G





Figure 1H





**Figure 2A**

Donor A




Donor B





**Figure 2A (continued)**

Donor C




Donor D





**Figure 2B**

Donor C - CD8




Donor C - NK




**Figure 2B (continued)**

Donor C - Vd1





**Figure 2C**

Donor A




Donor B





**Figure 2C (continued)**

Donor C




Donor D





**Figure 2D**

Donor C: CD8+ cells




Donor C: Vδ1 γδ T-cells





**Figure 2D (continued)**

Donor C: NK cells



## Figure 3 A-D

Figure 3A





Figure 3B





Figure 3C





Figure 3D




**Figure 3 E-H**

Figure 3E





Figure 3F





Figure 3G





Figure 3H




**Figure 3 I-L**

Figure 3I





Figure 3J





Figure 3K






Figure 3L



## Figure 3 M-P

Figure 3M





Figure 3N





Figure 3O





Figure 3P




**Figure 4 A-B**

Figure 4A





Figure 4B




**Figure 4 C-D**

Figure 4C





Figure 4D




**Figure 4 E-F**

Figure 4E





Figure 4F




**Figure 4 G-H**

Figure 4G






Figure 4H



## Figure 5 A-B

Figure 5A






Figure 5B



## Figure 5 C-D

Figure 5C






Figure 5D



## Figure 5 E-F

Figure 5E





Figure 5F




**Figure 6 A-D**




**Figure 7A**



Controls
Survival (%)
140
120
100
80
60
40
20
0
0.0001
0.01
1
100
10000
Concentration (nM)
duocarmycin type toxin
Zoledronate
HMBPP
XC1
XD1
pAg conjugates (1)
Survival (%)
140
120
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
Concentration (µg/mL)
Rituximab
ADC-XC4-r
ADC-XD4-r
ADC-XD13-r
ADC-XC4-i
ADC-XD4-i
ADC-XD13-i

**Figure 7A (continued)**




**Figure 7B**



pAg conjugates overview % survival at 10 µg/mL
Survival (%)
120
100
80
60
40
20
0
Rituximab
Isotype control
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XD13-i
ADC-XD4-i
ADC-XC4-i
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS2-i
ADC-XD18-i
ADC-XC9-i
ADC-XC13-i
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XS22-r
ADC-XS7-i
ADC-XS12-i
ADC-XS17-i
ADC-XS22-i

**Figure 8**



Vδ2 - CD107a
Donor A-1
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XC4-r
ADC-XC4-i
ADC-XD4-r
ADC-XD4-i
ADC-XD13-r
ADC-XD13-i
Rituximab
Vδ2 - CD107a
Donor B
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XC4-r
ADC-XC4-i
ADC-XD4-r
ADC-XD4-i
Rituximab

**Figure 8 (continued)**





**Figure 8 (continued)**







**Figure 8 (continued)**




**Figure 8 (continued)**




**Figure 8 (continued)**




**Figure 8 (continued)**




**Figure 8 (continued)**





**Figure 8 (continued)**








**Figure 8 (continued)**








**Figure 8 (continued)**







**Figure 9A**



CD107a EC50 summary
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
EC50 value > geomean EC50 value of rituximab
# and no full DRC / no activity

**Figure 9B**



IFNγ EC50 summary
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
EC50 value > geomean EC50 value of rituximab
# and no full DRC / no activity

**Figure 9C**



TNFα EC50 summary
EC50 (µg/mL)
#
10
1
0.1
0.01
0.001
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
EC50 value > geomean EC50 value of rituximab
# and no full DRC / no activity

**Figure 9D**



CD107a % activated Vδ2 γδ T cells summary
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
% activated cells > mean % activated cells of rituximab

**Figure 9E**



IFNγ % activated Vδ2 γδ T cells summary
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
% activated cells > mean % activated cells of rituximab

**Figure 9F**



TNFα % activated Vδ2 γδ T cells summary
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
% activated cells > mean % activated cells of rituximab

**Figure 9G**



CD107a MFI Vδ2 γδ T cells summary
CD107a MFI
15000
10000
5000
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
MFI > mean MFI of rituximab

**Figure 9H**



IFNγ MFI Vδ2 γδ T cells summary
IFNγ MFI
15000
10000
5000
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
MFI > mean MFI of rituximab

**Figure 9I**



TNFα MFI Vδ2 γδ T cells summary
TNFα MFI
20000
15000
10000
5000
0
Rituximab
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
MFI > mean MFI of rituximab

**Figure 10A**



CD107a vs IFNγ geomean EC50 summary
IFNγ geomean EC50 (µg/mL)
CD107a geomean EC50 (µg/mL)
0.01
0.1
1
10
#
*
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
Rituximab
# and no full DRC / no activity

**Figure 10B**



CD107a vs IFNγ % Efficacy summary
Mean % activated Vδ2 γδ T cells (IFNγ)
Mean % activated Vδ2 γδ T cells (CD107a)
0
20
40
60
80
100
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
Rituximab

**Figure 10C**



CD107a vs IFNγ MFI summary
Mean IFNγ MFI
Mean CD107a MFI
15000
10000
5000
0
0
5000
10000
15000
ADC-XC4-r
ADC-XD13-r
ADC-XD4-r
ADC-XS2-r
ADC-XD18-r
ADC-XC9-r
ADC-XC13-r
ADC-XS7-r
ADC-XS12-r
ADC-XS17-r
ADC-XD24-r
ADC-XS22-r
ADC-XS25-r
ADC-XD65-r
ADC-XD44-r
ADC-XD45-r
ADC-XD46-r
ADC-XD58-r
ADC-XD63-r
Rituximab

**Figure 11A**



CD107a EC50 summary DAR2 versus DAR8
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2
# and no full DRC / no activity

**Figure 11B**



IFNγ EC50 summary DAR2 versus DAR8
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2
# and no full DRC / no activity

**Figure 11C**



TNFα EC50 summary DAR2 versus DAR8
#
10
1
0.1
0.01
0.001
EC50 (µg/mL)
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2
# and no full DRC / no activity

**Figure 11D**



CD107a % activated Vδ2 γδ T cells summary DAR2 versus DAR8
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2

**Figure 11E**



IFNγ % activated Vδ2 γδ T cells summary DAR2 versus DAR8
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2

**Figure 11F**



TNFα % activated Vδ2 γδ T cells summary DAR2 versus DAR8
% activated Vδ2 γδ T cells
100
90
80
70
60
50
40
30
20
10
0
ADC-XD65-r
ADC8-XD65-r
Rituximab
Donor O
Donor A-2

Figure 12A



Donor AL
% dead Raji cells
100
80
60
40
20
0
+
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
Concentration (µg/mL)
Donor AM
% dead Raji cells
80
60
40
20
0
+
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
Concentration (µg/mL)

**Figure 12A (continued)**





**Figure 12A (continued)**







**Figure 12A (continued)**




**Figure 12A (continued)**




**Figure 12B**





**Figure 12C**







**Figure 12D**


Efficacy (%)
Efficacy (%)
80
60
40
20
0
Rituximab
ADC-XD18-r
ADC-XD18-i
Symbol shape
Donor R
Donor AJ
Donor AL
Donor AM
Donor AN
Donor AO
Donor AP
Donor AQ
Donor AR


# Figure 13A


HMBPP
Vδ2 CD107a % activated all cell lines
% activated
100
80
60
40
20
0
Donor Q
Donor AH
Raji
HG-3
MEC-1
SU-DHL-4
SU-DHL-8


## Figure 13B


Vδ2 γδ T cells - CD107a
Raji
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
Raji
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab


## Figure 13C


Vδ2 γδ T cells - CD107a
HG-3
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
HG-3
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

## Figure 13D


Vδ2 γδ T cells - CD107a
MEC-1
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
MEC-1
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

## Figure 13E


Vδ2 γδ T cells - CD107a
SU-DHL-4
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
SU-DHL-4
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

## Figure 13F



Vδ2 γδ T cells - CD107a
SU-DHL-8
Donor Q
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab
Vδ2 γδ T cells - CD107a
SU-DHL-8
Donor AH
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC-XD18-i
rituximab

Figure 14A





Figure 14B




Figure 14C





Figure 14D




**Figure 14E**





**Figure 14F**




**Figure 14G**





**Figure 14H**




Figure 14I





Figure 14J




**Figure 14K**





**Figure 14L**




Figure 15A





Figure 15B




Figure 15C





Figure 15D




Figure 15E





Figure 15F




Figure 16A





Figure 16B




**Figure 16C**



Vδ2 γδ T cells - TNFα
% activated cells
% activated cells
100
80
60
40
20
0
BT-474
SK-BR-3
SK-OV-3
HCT-116
Symbol shape
Donor F
Donor Y
Donor Z
Donor AU

Figure 17A





Figure 17B




Figure 17C





Figure 17D







**Figure 18A**


HMBPP
Vδ2 CD107a % activated all donors
% activated
100
80
60
40
20
0
Raji
MOLM-13
Donor AC
Donor AD
Donor AE
Donor AF


## Figure 18B


Vδ2 γδ T cells - CD107a
Donor AC
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AC
% activated cells
Concentration (µg/mL)
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
ADC-XD18-i41C
ADC8-XD18-i
ADC16-XD59-i
anti-CD12341C

## Figure 18C


Vδ2 γδ T cells - CD107a
Donor AD
% activated cells
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AD
% activated cells
Concentration (µg/mL)
ADC-XD18-CD123 41C
ADC10-XD18-CD123 41C
ADC20-XD59-CD123 41C
ADC-XD18-i 41C
ADC16-XD59-i
ADC16-XD59-i
anti-CD123 41C

## Figure 18D


Vδ2 γδ T cells - CD107a
Donor AE
% activated cells
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AE
% activated cells
Concentration (µg/mL)
ADC-XD18-CD123 41C
ADC10-XD18-CD123 41C
ADC20-XD59-CD123 41C
ADC-XD18-i41C
ADC8-XD18-i
ADC16-XD59-i
anti-CD123 41C

## Figure 18E



Vδ2 γδ T cells - CD107a
Donor AF
% activated cells
100
80
60
40
20
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (µg/mL)
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
ADC-XD18-i
ADC8-XD18-i
ADC16-XD59-i
rituximab
Vδ2 γδ T cells - CD107a
Donor AF
% activated cells
Concentration (µg/mL)
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
ADC-XD18-i41C
ADC8-XD18-i
ADC16-XD59-i
anti-CD12341C

**Figure 18F**



Vδ2 - CD107a EC50 all donors
Raji
EC50 (µg/ml)
10
1
0.1
0.01
0.001
Rituximab
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
Donor AC
Donor AD
Donor AE
Donor AF
Vδ2 - CD107a EC50 all donors
MOLM-13
EC50 (µg/ml)
#
100
10
1
0.1
0.01
0.001
anti-CD12341C
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
Donor AC
Donor AD
Donor AE
Donor AF
# No full DRC/ no activity

**Figure 18G**




Vδ2 - CD107a % activated all donors
Raji
% activated
100
80
60
40
20
0
Rituximab
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
Donor AC
Donor AD
Donor AE
Donor AF
Vδ2 - CD107a % activated all donors
MOLM-13
% activated
100
80
60
40
20
0
anti-CD12341C
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
Donor AC
Donor AD
Donor AE
Donor AF

**Figure 18H**


Vδ2 - CD107a MFI all donors
Raji
MFI
8000
6000
4000
2000
0
Rituximab
ADC-XD18-r
ADC8-XD18-r
ADC16-XD59-r
Donor AC
Donor AD
Donor AE
Donor AF
Vδ2 - CD107a MFI all donors
MOLM-13
MFI
5000
4000
3000
2000
1000
0
anti-CD12341C
ADC-XD18-CD12341C
ADC10-XD18-CD12341C
ADC20-XD59-CD12341C
Donor AC
Donor AD
Donor AE
Donor AF